Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations.A. Inoue, Kenichi Kobayashi, Makoto Maemondo et al.|Journal of Clinical Oncology|2011Cited by 37
NEJ026: Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutationsMakoto Maemondo, T. Nukiwa, Tatsuro Fukuhara et al.|Annals of Oncology|2016Cited by 6
3064 NEJ016: Phase II study of carboplatin and weekly paclitaxel plus bevacizumab followed by bevacizumab for highly selected elderly non-squamous non-small cell lung cancer patientsTeruichi Harada, H. Yoshizawa, Keigo Kobayashi et al.|European Journal of Cancer|2015Cited by 0